

Methods and Processes of the CONSORT Group: Example of an Extension for Trials Assessing Nonpharmacologic Treatments

Isabelle Boutron, MD, PhD; David Moher, PhD; Douglas G. Altman, DSc; Kenneth F. Schulz, PhD, MBA; and Philippe Ravaud, MD, PhD, for the CONSORT Group*

Background: The conduct of randomized, controlled trials of nonpharmacologic treatments presents specific challenges that are not adequately addressed in trial reports.

Objective: To develop an extension of the CONSORT (Consolidated Standards of Reporting Trials) Statement for trials of nonpharmacologic treatments.

Design: A consensus meeting was organized to develop an extension of the CONSORT Statement that addresses randomized trials of nonpharmacologic treatments. To prepare for the meeting, a survey was conducted to identify the specific issues for discussion.

Setting: Consensus meeting in Paris, France.

Participants: A total of 33 experts attended the meeting. The experts were methodologists ($n = 17$); surgeons ($n = 6$); editors ($n = 5$); and clinicians involved in rehabilitation ($n = 1$), psychotherapy ($n = 2$), education ($n = 1$), and implantable devices ($n = 1$).

Measurements: Experts indicated which of the 22 items on the CONSORT checklist should be modified or which additional items should be added specifically for nonpharmacologic treatments. During a 3-day consensus meeting, all items were discussed and ad-

ditional methodological issues related to nonpharmacologic research were identified.

Results: The consensus was that 11 items on the CONSORT checklist needed some modifications for nonpharmacologic trials: item 1 (title and abstract), item 3 (participants), item 4 (interventions), item 7 (sample size), item 8 (randomization), item 11 (blinding), item 12 (statistical methods), item 13 (participant flow), item 15 (baseline data), item 20 (discussion: interpretation), and item 21 (generalizability). In addition, the meeting participants added 1 item related to implementation of the intervention.

Limitation: Evidence was not always available to support the inclusion of each checklist item.

Conclusion: The methods and processes used to develop this extension could be used for other reporting guidelines. The use of this extension to the CONSORT Statement should improve the quality of reporting randomized, controlled trials assessing nonpharmacologic treatments.

Ann Intern Med. 2008;148:W-60-W-66.

www.annals.org

For author affiliations, see end of text.

*For contributors to the CONSORT Extension for Nonpharmacologic Treatment Interventions, see the **Appendix**.

Randomized, controlled trials (RCTs) are considered the gold standard for evaluation of drugs, devices, and procedures. To help improve the quality of reporting of these trials, the CONSORT (Consolidated Standards of Reporting Trials) Statement, a 22-item checklist and flow diagram, was developed. Use of this evidence-based guideline is associated with improved quality of reporting of RCTs (1, 2). The original CONSORT Statement proposed guidelines for reporting 2-group parallel RCTs (3, 4). The CONSORT Statement has subsequently been extended to cover specific variants of this design, such as cluster randomized trials (5) and noninferiority and equivalence trials (6); certain interventions, such as herbal therapies (7); and data, such as reporting of harms (8).

Nonpharmacologic treatments cover a wide range of interventions, including surgery, technical procedures (for

example, angioplasty), implanted devices (for example, pacemakers), nonimplantable devices, rehabilitation, physiotherapy, behavioral therapy, psychotherapy, and complementary and alternative medicine. Although the CONSORT Statement can be applied to reports of these trials, certain issues, such as the complexity of the intervention, expertise of the care provider, and difficulties with blinding (9), present specific challenges that the revised CONSORT Statement and the accompanying explanation and elaboration document do not address in depth (3, 4, 9–13).

Because these important study aspects are often inadequately reported (3), we developed an extension of the CONSORT Statement for trials of nonpharmacologic interventions (14–17). This article describes the methods and processes used by the CONSORT Group to develop this extension.

METHODS

To develop the CONSORT extension for nonpharmacologic treatments, we used general guideline development principles (18) and drew on the experience gained from developing previous CONSORT extensions (19).

Steering Committee

A steering committee was ultimately responsible for the development of this reporting guide. They secured

See also:

Print

Related article. 295

Web-Only

Appendix

Conversion of graphics into slides

funding, reviewed the literature, identified participants to invite to a consensus meeting, conducted a survey to identify specific issues related to the assessment of nonpharmacologic treatments, and organized the CONSORT consensus meeting (agenda, identification of the topics to be discussed, organization of presentations, and methods of consensus).

Funding

Funding is essential to enable the development of any reporting guideline. For this guidance, we obtained funding to develop a Web-based survey and have the consensus meeting. The funding was used solely to cover the expenses of participants coming to the meeting. Members of the steering committee were funded by their respective home institutions.

Funding of this extension was obtained primarily from nonindustry sources: the Department of Clinical Research of the Assistance Publique des Hôpitaux de Paris (Paris, France); the Department of Epidemiology, Biostatistics, and Clinical Research of the Bichat Hospital (Paris, France); INSERM (Institut National de la Santé et de la Recherche Médicale) (Paris, France); and the Eli Lilly Institute (Suresnes, France), which is a French association providing unrestricted research and education grants.

Identification of Participants

Our aim was to bring together clinical epidemiologists and statisticians who published methodological papers on issues involved in the assessment of nonpharmacologic treatments and clinicians in various fields who participated in the design, conduct, and analyses of RCTs of nonpharmacologic treatments. In addition, we invited editors of journals that publish trials of nonpharmacologic treatment and other editors with expertise and experience in developing reporting guidelines.

On the basis of previous experiences in developing reporting guidelines, we limited the number of participants to 40. This was done because funding was limited and to allow maximum interaction during the meeting. When an originally nominated invitee suggested additional invitees, we invited them if their domain of expertise was not already sufficiently represented and the total number of participants was still fewer than 40.

Thirty-seven experts were invited to participate in the consensus meeting. The 33 attendees comprised methodologists ($n = 17$); surgeons ($n = 6$); medical journal editors ($n = 5$); and clinicians involved in rehabilitation ($n = 1$), psychotherapy ($n = 2$), education ($n = 1$), and implantable devices ($n = 1$). These are nominal frequencies for each category, as several participants had more than 1 domain of expertise.

Identification of Specific Issues

Before the meeting, the steering group surveyed meeting invitees by using a Web-based questionnaire to identify specific issues that should be discussed during the meeting. Invitees were asked to suggest which of the 22 items on the

CONSORT Statement might need to be modified for the proposed nonpharmacologic treatments extension. The Web-based interface is available at www.nonpharmacological.com/ConsortExtension/consort05.php.

On the basis of the results of a systematic review of the topic (9), respondents were asked whether they believed we should add the following 7 items.

Methods section: 1) eligibility criteria for care providers (for example, surgeons, physiotherapists, or psychologists) included in the trial and 2) the centers' volume for the procedure or similar procedures (as a proxy for experience).

Results section: 1) the number of care providers performing the treatment in each group, 2) the number of participants treated by each care provider, 3) participants' expectancies or preference for the treatments at baseline, 4) baseline data on care providers, and 5) care providers' compliance with the planned procedure.

Invitees were also asked to nominate additional items they felt were particularly important when evaluating nonpharmacologic treatments.

When more than one third of the respondents rated an item as needing modification or said that an additional item should be added, that item was selected by the steering committee as a high priority for discussion during the meeting. Items rated by fewer than one third of the respondents were given a lower priority.

Consensus Meeting

A 3-day consensus meeting was held in February 2006 in Paris, France. The meeting began with several presentations on specific topics related to the reporting of nonpharmacologic treatments (complexity of the intervention, influence of centers and care providers, clustering effect, blinding, assessment of harms, external validity). These presentations were selected by the steering committee to facilitate additional discussion during the meeting.

Participants then introduced and discussed each item proposed for modification or as an addition to the checklist until they reached a consensus. At least 1 member of the steering group moderated these discussions. The participants then considered the remaining CONSORT checklist items, which were given lower priorities, to see whether additional modifications were needed. All of these discussions were recorded, and minutes of the meeting were prepared.

The meeting concluded with a discussion of optimal dissemination and publication strategies in light of other CONSORT extensions.

Reporting Guidelines

After the meeting, the steering committee circulated a draft of the CONSORT extensions for nonpharmacologic treatments to all meeting participants for feedback. The steering committee collated the participants' comments and suggested revisions and developed a paper describing the new extension to the CONSORT Statement. The participants subsequently revised the document to ensure that

Table 1. Results of the Survey on Revisions and Additions to the CONSORT Checklist*

CONSORT Checklist Items	Item	Respondents, n (%)†
Preexisting checklist items considered for modification		
Title and abstract‡	1	13 (50)
Introduction		
Background	2	6 (23)
Methods		
Participants	3	8 (31)
Interventions‡	4	19 (73)
Objectives	5	6 (23)
Outcomes	6	8 (31)
Sample size‡	7	10 (38)
Randomization: sequence generation‡	8	9 (35)
Randomization: allocation concealment	9	5 (19)
Randomization: implementation	10	3 (11)
Blinding (masking)‡	11	15 (58)
Statistical methods‡	12	11 (42)
Results		
Participant flow	13	6 (23)
Recruitment	14	5 (19)
Baseline data	15	5 (19)
Numbers analyzed	16	3 (11)
Outcomes and estimation	17	2 (8)
Ancillary analyses	18	6 (23)
Adverse events	19	6 (23)
Discussion		
Interpretation‡	20	9 (35)
Generalizability‡	21	11 (42)
Overall evidence	22	1 (4)
Additional items proposed by the steering committee		
Methods		
Eligibility criteria for care providers	–	26 (100)
Details on the centers' volume	–	20 (77)
Results		
Number of care providers performing the treatment in each group	–	23 (88)
Number of participants treated by each care provider	–	23 (88)
Details on patients' expectancies or preference for the treatments at baseline	–	11 (42)
Baseline data of care providers	–	23 (88)
Details on care providers' compliance with the planned procedure	–	20 (77)

* CONSORT = Consolidated Standards of Reporting Trials.

† The maximum number of possible respondents was 26.

‡ Items were selected for further discussion.

it accurately represented the decisions made during the meeting.

RESULTS

Twenty-six of the 30 meeting invitees (apart from the 3 members of the steering committee) completed the survey. Eight CONSORT checklist items were selected for further discussion during the meeting (Table 1). These items dealt mainly with reporting the methods of a non-pharmacologic treatment trial. No checklist item in the results section was selected for modification by more than one third of the participants. In contrast, there was substantial concurrence (77% to 100%) among the survey respondents regarding the 7 specific issues suggested for further discussion, except for “details on patients' expectation or preference for the treatments at baseline” (Table 1).

Respondents provided several comments to explain their choice. These comments were grouped by the steering committee into 5 sections: 1) the level of complexity of

nonpharmacologic treatments that implies the need to report all the components of the intervention, co-interventions, method of standardizing the treatment, and compliance of care providers with the planned protocol; 2) the influence of care provider and center volume on estimates of treatment effect, with the difficulties of having an adequate proxy to describe care providers—the possible proxy could address care providers' experience, qualification, years of practice, specific training, skill, and learning curve (that is, the relationship between the experience of a surgeon and 1 or more performance indicators); 3) the statistical analyses, with the need to take into account the clustering of outcomes of patients treated by the same care provider or center in the sample size calculation and the statistical analyses; 4) the difficulties of blinding; and 5) the generalizability with regard to the comparator and care providers and centers.

The meeting participants recommended modifications to 11 checklist items (Table 2). In addition, the group


Table 2. Checklist of Items for Reporting Trials of Nonpharmacologic Treatments*

Section	Item	Standard CONSORT Description	Extension for Nonpharmacologic Trials
Title and abstract	1	How participants were allocated to interventions (e.g., "random allocation," "randomized," or "randomly assigned")	In the abstract, description of the experimental treatment, comparator, care providers, centers, and blinding status
Introduction			
Background	2	Scientific background and explanation of rationale	
Methods			
Participants	3	Eligibility criteria for participants and the settings and locations where the data were collected	When applicable, eligibility criteria for centers and those performing the interventions
Interventions	4	Precise details of the interventions intended for each group and how and when they were actually administered	Precise details of both the experimental treatment and comparator
	4A		Description of the different components of the interventions and, when applicable, descriptions of the procedure for tailoring the interventions to individual participants
	4B		Details of how the interventions were standardized
	4C		Details of how adherence of care providers with the protocol was assessed or enhanced
Objectives	5	Specific objectives and hypotheses	
Outcomes	6	Clearly defined primary and secondary outcome measures and, when applicable, any methods used to enhance the quality of measurements (e.g., multiple observations, training of assessors)	
Sample size	7	How sample size was determined and, when applicable, explanation of any interim analyses and stopping rules	When applicable, details of whether and how the clustering by care providers or centers was addressed
Randomization-sequence generation	8	Method used to generate the random allocation sequence, including details of any restriction (e.g., blocking, stratification)	When applicable, how care providers were allocated to each trial group
Allocation concealment	9	Method used to implement the random allocation sequence (e.g., numbered containers or central telephone), clarifying whether the sequence was concealed until interventions were assigned	
Implementation	10	Who generated the allocation sequence, who enrolled participants, and who assigned participants to their groups	
Blinding (masking)	11A	Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment	Whether or not those administering co-interventions were blinded to group assignment
	11B†		If blinded, method of blinding and description of the similarity of interventions†
Statistical methods	12	Statistical methods used to compare groups for primary outcome(s); methods for additional analyses, such as subgroup analyses and adjusted analyses	When applicable, details of whether and how the clustering by care providers or centers was addressed
Results			
Participant flow	13	Flow of participants through each stage (a diagram is strongly recommended)—specifically, for each group, report the numbers of participants randomly assigned, receiving intended treatment, completing the study protocol, and analyzed for the primary outcome; describe protocol deviations from study as planned, together with reasons	The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider or in each center
Implementation of intervention	New item		Details of the experimental treatment and comparator as they were implemented
Recruitment	14	Dates defining the periods of recruitment and follow-up	
Baseline data	15	Baseline demographic and clinical characteristics of each group	When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group
Numbers analyzed	16	Number of participants (denominator) in each group included in each analysis and whether analysis was by "intention-to-treat"; state the results in absolute numbers when feasible (e.g., 10/20, not 50%)	
Outcomes and estimation	17	For each primary and secondary outcome, a summary of results for each group and the estimated effect size and its precision (e.g., 95% confidence interval)	
Ancillary analyses	18	Address multiplicity by reporting any other analyses performed, including subgroup analyses and adjusted analyses, indicating those prespecified and those exploratory	
Adverse events	19	All important adverse events or side effects in each intervention group	
Discussion			
Interpretation	20	Interpretation of the results, taking into account study hypotheses, sources of potential bias or imprecision, and the dangers associated with multiplicity of analyses and outcomes	In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group
Generalizability	21	Generalizability (external validity) of the trial findings	Generalizability (external validity) of the trial findings according to the intervention, comparators, patients, and care providers and centers involved in the trial
Overall evidence	22	General interpretation of the results in the context of current evidence	

* Additions or modifications to the CONSORT checklist. CONSORT = Consolidated Standards of Reporting Trials.

† This item anticipates a planned revision in the next version of the standard CONSORT checklist.

Figure. Modified CONSORT flow diagram for individual randomized, controlled trials of nonpharmacologic treatment.



An extra box for each intervention group relating to care providers has been added. For cluster randomized, controlled trials, authors should refer to the appropriate extension. IQR = interquartile range; max = maximum; min = minimum.

agreed to add 1 new checklist item, related to implementation of the intervention. Some of these recommendations begin with “when applicable” to indicate that not all the information authors are encouraged to report is applicable for every nonpharmacologic treatment trial. For example, the reporting of centers’ volume is probably more appropriate for surgical and technical procedures than for rehabilitation. Item 11 (blinding) was modified to reflect the change in wording of this item in the proposed revision to the 2001 CONSORT Statement, as discussed during the last CONSORT meeting in Montebello, Québec, Canada, in January 2007 (Moher D. Personal communication.).

Meeting participants modified the CONSORT flow

diagram to include data on the number of care providers and centers in each group, as well as the number of patients treated by each care provider (Figure).

The checklist and flow diagram are available on the CONSORT Web site (www.consort-statement.org). They can be freely downloaded and copied for noncommercial purposes without any modifications, as long as a full citation is provided. For full details on conditions of use, consult the CONSORT Web site.

During the meeting, participants encouraged the development of an explanation and elaboration document similar to those developed for other reporting guidelines (4, 20–22). We felt that such an effort would facilitate the understanding and dissemination of the nonpharmacologic treatment checklist and flow diagram. We developed the document by using a standard template (19). Each item is introduced, after which the rationale and evidence for the need to report the item (when available) are presented, and an example of reporting in tabular format is provided. To clarify the extra information sought for in nonpharmacologic trials, this CONSORT extension presents the additional text separately from the text of the original CONSORT item rather than as merged text, as has been done previously.

The meeting participants also proposed developing specific explanation and elaboration documents for different categories of nonpharmacologic treatments, such as surgery, rehabilitation, and behavioral interventions. We will develop these documents by using an approach similar to the one described here.

Finally, the meeting participants discussed in detail the issue of how best to use the CONSORT Statement and its extensions to report trials that cut across specific reporting guidelines (for example, trials on the use of both pharmaceutical and surgical interventions, or trials using a cluster or equivalence design). The CONSORT Group is currently developing a Web-based interface to allow authors to select combinations of specific checklists and flow diagrams to help them report their trials. That interface will be available from the CONSORT Web site (www.consort-statement.org).

DISCUSSION

Although journal adoption of the CONSORT Statement is associated with improved quality of reporting (1), the reporting of trials of nonpharmacologic treatments remains suboptimal, especially with regard to such issues as the description of the interventions and the volume of care providers and centers (14, 23–27). To help improve this situation, the CONSORT Group has developed this extension of the CONSORT Statement.

This article describes the current methods used by the CONSORT Group to develop their reporting guidelines. Development of evidence-based reporting guidelines is a

new and evolving area. Some initial ideas have been proposed to enhance the development process, and therefore the validity of the guidelines it produces (19).

First, development should involve a broad range of participants representing different perspectives, areas of expertise, and experiences. The participants in this meeting included clinical trialists in various fields, methodologists, statisticians, and journal editors. Second, substantive preparations and data gathering should precede the meeting. For this extension, we completed an extensive review of the literature on bias when assessing nonpharmacologic treatments (9). We also completed a survey of the surgical literature by assessing the quality of reports of 158 surgical intervention trials and developed a quality tool (14, 28). All of these steps helped to ensure that the foundation for developing this extension was as evidence-based as possible.

This reporting guideline builds on the 2001 version of the 22-item CONSORT checklist and flow diagram. A Web-based preliminary survey was very useful in identifying which items needed further discussion and which new items should be included. Finally, the meeting organized to develop this extension took the form of very structured discussions led by different chairs.

The publication of this extension of the CONSORT Statement is an essential step to further its dissemination. To provide a more thorough understanding of the checklist, we developed an explanation and elaboration document (29) to be used in conjunction with this extension. That explanation and elaboration document should be considered in conjunction with the 2001 CONSORT explanation and elaboration paper (4).

In conclusion, this article provides a detailed description of the methods and processes used to develop the CONSORT extension for nonpharmacologic treatments. Describing these methods allows readers to judge the validity of the process and the subsequent reporting guideline.

We believe that the use of this extension will improve the reporting of trials on nonpharmacologic treatment. As with all CONSORT guidelines, these reporting recommendations are evolving and require periodic reevaluation. The CONSORT Group will continue to survey the literature, and we invite authors of any interesting articles to notify us about them.

Many journals have endorsed the CONSORT Statement, modified their instructions to authors, and asked authors to adhere to the checklist and flow diagram when submitting a report of their RCT. We hope that these journals will also endorse this CONSORT extension for reporting nonpharmacologic treatments and ask authors to adhere to it. In addition, we invite journals that have not yet endorsed the CONSORT Statement and its extensions, including CONSORT for nonpharmacologic trials, to do so by modifying their instructions to authors accordingly. They can alert the CONSORT Group of such actions

through the CONSORT Web site (www.consort-statement.org).

APPENDIX: CONTRIBUTORS TO THE CONSORT EXTENSION FOR NONPHARMACOLOGIC TREATMENT INTERVENTIONS

Douglas G. Altman (University of Oxford, Oxford, United Kingdom); Mohit Bhandari (McMaster University, Hamilton General Hospital, McMaster Clinic, Hamilton, Ontario, Canada); Isabelle Boutron (INSERM U738, AP-HP, Hôpital Bichat-Claude Bernard, and Université Paris 7 Denis Diderot, Paris, France); Marion Campbell (Health Services Research Unit, Aberdeen, United Kingdom); Philip Devereaux (McMaster University Health Sciences Centre, Hamilton, Ontario, Canada); Peter C. Gøtzsche (The Nordic Cochrane Centre, Copenhagen, Denmark); Teodor P. Grantcharov (Saint Michael's Hospital, Toronto, Ontario, Canada); Jeremy Grimshaw (Ottawa Health Research Institute, Ottawa, Ontario, Canada); Ethan A. Halm (Mount Sinai School of Medicine, New York, New York); Erik Hendriks (Maastricht University, Maastricht, the Netherlands); Asbjørn Hróbjartsson (The Nordic Cochrane Centre, Copenhagen, Denmark); John Ioannidis (University of Ioannina School of Medicine and Biomedical Research Institute, Foundation for Research and Technology–Hellas, Ioannina, Greece); Astrid James (*The Lancet*, London, United Kingdom); Giselle Jones (*BMJ* Editorial, London, United Kingdom); Richard J. Lilford (University of Birmingham, Edgbaston, Birmingham, United Kingdom); Robin McLeod (*Annals of Surgery* and Mount Sinai Hospital, Toronto, Ontario, Canada); David Moher (Chalmers Research Group, Children's Hospital of Eastern Ontario Research Institute, and University of Ottawa, Ottawa, Ontario, Canada); Andrew J. Molyneux (Neurovascular Research Unit, Radcliffe Infirmary, Oxford, United Kingdom); Victor M. Montori (Mayo Clinic College of Medicine, Rochester, Minnesota); Cynthia Mulrow (*Annals of Internal Medicine*, American College of Physicians, Philadelphia, Pennsylvania); Amy Plint (Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada); Philippe Ravaud (INSERM U738, AP-HP, Hôpital Bichat-Claude Bernard, and Université Paris 7 Denis Diderot, Paris, France); Drummond Rennie (*JAMA*, Chicago, Illinois, and University of California, San Francisco, San Francisco, California); Peter M. Rothwell (Radcliffe Infirmary, Oxford, United Kingdom); Paula P. Schnurr (Veterans Affairs Medical and Regional Office Center, White River Junction, Vermont); Kenneth F. Schulz (Quantitative Sciences, Family Health International, Research Triangle Park, North Carolina); Christoph M. Seiler (University of Heidelberg Medical School, Heidelberg, Germany); Judith Stephenson (Centre for Sexual Health and HIV Research, Research Unit, London, United Kingdom); Simon G. Thompson (Medical Research Council, Biostatistics Unit, Institute of Public Health, Cambridge, United Kingdom); Graham Thornicroft (Institute of Psychiatry, King's College London, London, United Kingdom); David Torgerson (University of York, York, United Kingdom); Tom Treasure (Guy's and St Thomas' Hospital, London, United Kingdom); Peter Tugwell (*Journal of Clinical Epidemiology* and University of Ottawa, Ottawa, Ontario, Canada).

From INSERM U738, AP-HP, Hôpital Bichat-Claude Bernard, and Université Paris 7 Denis Diderot, Paris, France; Chalmers Research Group, Children's Hospital of Eastern Ontario Research Unit, University of Ottawa, Ottawa, Ontario, Canada; University of Oxford, Oxford, United Kingdom; and Family Health International, Research Triangle Park, North Carolina.

Acknowledgment: The authors thank Lola Fourcade, who was responsible for preparing the minutes of the CONSORT meeting, and Lucie Ronceray, who developed the Web-based interface used for the preliminary survey.

Grant Support: By the Département de la Recherche Clinique et du Développement, Assistance Publique des Hôpitaux de Paris; Département d'Epidémiologie, Biostatistique et Recherche Clinique, Hôpital Bichat-Claude Bernard; INSERM U738; and the Eli Lilly Institute. Dr. Moher is funded in part by a University of Ottawa Research Chair. Dr. Altman is supported by Cancer Research UK. Dr. Schulz is supported by Family Health International.

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Isabelle Boutron, MD, PhD, Département d'Epidémiologie Biostatistique et Recherche Clinique, INSERM U738, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris 7 Denis Diderot, 46 rue Henri Huchard, 75018 Paris, France; e-mail, isabelle.boutron@bch.aphp.fr.

Current Author Addresses: Drs. Boutron and Ravaud: Département d'Epidémiologie Biostatistique et Recherche Clinique, INSERM U738, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris 7 Denis Diderot, 46 rue Henri Huchard, 75018 Paris, France.

Dr. Moher: Chalmers Research Group, Children's Hospital of Eastern Ontario Research Institute, Faculty of Medicine, University of Ottawa, 401 Smyth Road, Room 210, Ottawa, Ontario, Canada.

Dr. Altman: Centre for Statistics in Medicine, University of Oxford, Wolfson College Annexe, Linton Road, Oxford OX2 6UD, United Kingdom.

Dr. Schulz: Quantitative Sciences, Family Health International, PO Box 13950, Research Triangle Park, NC 27709.

References

1. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. *Med J Aust.* 2006;185:263-7. [PMID: 16948622]
2. Moher D, Jones A, Lepage L; CONSORT Group (Consolidated Standards for Reporting of Trials). Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. *JAMA.* 2001;285:1992-5. [PMID: 11308436]
3. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. *Lancet.* 2001;357:1191-4. [PMID: 11323066]
4. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al; CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: explanation and elaboration. *Ann Intern Med.* 2001;134:663-94. [PMID: 11304107]
5. Campbell MK, Elbourne DR, Altman DG; CONSORT group. CONSORT statement: extension to cluster randomised trials. *BMJ.* 2004;328:702-8. [PMID: 15031246]
6. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. *JAMA.* 2006;295:1152-60. [PMID: 16522836]
7. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C; CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. *Ann Intern Med.* 2006;144:364-7. [PMID: 16520478]
8. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al; CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. *Ann Intern Med.* 2004;141:781-8. [PMID: 15545678]
9. Boutron I, Tubach F, Giraudeau B, Ravaud P. Methodological differences in clinical trials evaluating nonpharmacological and pharmacological treatments of hip and knee osteoarthritis. *JAMA.* 2003;290:1062-70. [PMID: 12941679]
10. Stephenson J, Imrie J. Why do we need randomised controlled trials to assess behavioural interventions? *BMJ.* 1998;316:611-3. [PMID: 9518919]
11. Lilford R, Braunholtz D, Harris J, Gill T. Trials in surgery. *Br J Surg.* 2004;91:6-16. [PMID: 14716788]
12. McCulloch P, Taylor I, Sasako M, Lovett B, Griffin D. Randomised trials in surgery: problems and possible solutions. *BMJ.* 2002;324:1448-51. [PMID: 12065273]
13. Ravaud P, Boutron I. Primer: assessing the efficacy and safety of nonpharmacologic treatments for chronic rheumatic diseases. *Nat Clin Pract Rheumatol.* 2006;2:313-9. [PMID: 16932710]
14. Jacquier I, Boutron I, Moher D, Roy C, Ravaud P. The reporting of randomized clinical trials using a surgical intervention is in need of immediate improvement: a systematic review. *Ann Surg.* 2006;244:677-83. [PMID: 17060758]
15. Manterola C, Pineda V, Vial M, Losada H; MINCIR Group. What is the methodologic quality of human therapy studies in ISI surgical publications? *Ann Surg.* 2006;244:827-32. [PMID: 17060778]
16. McLeod R. Randomized, controlled trials: is there a role for them in surgery? [Editorial]. *Ann Surg.* 2006;244:684-5. [PMID: 17060759]
17. Balasubramanian SP, Wiener M, Alshameeri Z, Tiruvoipati R, Elbourne D, Reed MW. Standards of reporting of randomized controlled trials in general surgery: can we do better? *Ann Surg.* 2006;244:663-7. [PMID: 17060756]
18. Woolf SH. Practice guidelines, a new reality in medicine. II. Methods of developing guidelines. *Arch Intern Med.* 1992;152:946-52. [PMID: 1580720]
19. Altman DG, Moher D. [Developing guidelines for reporting healthcare research: scientific rationale and procedures.]. *Med Clin (Barc).* 2005;125:8-13. [PMID: 16464421]
20. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al; Standards for Reporting of Diagnostic Accuracy. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. *Ann Intern Med.* 2003;138:W1-12. [PMID: 12513067]
21. Vandembroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Ann Intern Med.* 2007;147:W163-94. [PMID: 17938389]
22. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandembroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med.* 2007;147:573-7. [PMID: 17938396]
23. Bhandari M, Guyatt GH, Lochner H, Sprague S, Tornetta P 3rd. Application of the Consolidated Standards of Reporting Trials (CONSORT) in the Fracture Care Literature. *J Bone Joint Surg Am.* 2002;84-A:485-9. [PMID: 11886922]
24. Bhandari M, Richards RR, Sprague S, Schemitsch EH. The quality of reporting of randomized trials in the Journal of Bone and Joint Surgery from 1988 through 2000. *J Bone Joint Surg Am.* 2002;84-A:388-96. [PMID: 11886908]
25. Dijkers M, Kropp GC, Esper RM, Yavuzer G, Cullen N, Bakdali Y. Quality of intervention research reporting in medical rehabilitation journals. *Am J Phys Med Rehabil.* 2002;81:21-33. [PMID: 11807328]
26. Ellis C, Hall JL, Khalil A, Hall JC. Evolution of methodological standards in surgical trials. *ANZ J Surg.* 2005;75:874-7. [PMID: 16176230]
27. Anyanwu AC, Treasure T. Surgical research revisited: clinical trials in the cardiothoracic surgical literature. *Eur J Cardiothorac Surg.* 2004;25:299-303. [PMID: 15019652]
28. Boutron I, Moher D, Tugwell P, Giraudeau B, Poiraudou S, Nizard R, et al. A checklist to evaluate a report of a nonpharmacological trial (CLEAR NPT) was developed using consensus. *J Clin Epidemiol.* 2005;58:1233-40. [PMID: 16291467]
29. Boutron I, Moher D, Altman DG, Schulz K, Ravaud P; for the CONSORT Group. Extending the CONSORT Statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. *Ann Intern Med.* 2008;148:295-309.